Close

Recherche clinique en oncologie

Type de cancerAcronymeNuméro NCTTitrePhaseStadeBiomarqueursLigne de traitementSitePersonne contact
Endometrial cancer2870-005MK-2870 in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005),MK-2870 dans le cancer de l'endomètre post-platine et post-immunothérapie (MK-2870-005)PHASE3RECURRENT, REFRACTORYN/AGREATER_THAN_SECOND_LINEMcGill University Health CentrePhuong-Nam Nathalie Nguyen phuong-nam.nguyen@mail.mcgill.ca 514 934-1934 #23985
Endometrial cancer2870-005MK-2870 in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005),MK-2870 dans le cancer de l'endomètre post-platine et post-immunothérapie (MK-2870-005)PHASE3RECURRENT, REFRACTORYN/AGREATER_THAN_SECOND_LINECIUSSS du Saguenay-Lac-Saint-JeanSabrina Côté, Katryne Lepage
Endometrial cancer2870-005
NCT06132958
MK-2870 in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005),MK-2870 dans le cancer de l'endomètre post-platine et post-immunothérapie (MK-2870-005)PHASE3RECURRENT, REFRACTORYN/AGREATER_THAN_SECOND_LINECentre hospitalier de l'Université de Montréal06CHUMDREC Recherche Clinique Gynécologie-oncologie
Ovarian CancerA10-M84-07A
NCT02296307
DOvEE - Diagnosing Ovarian & Endometrial Cancer EarlyNAPREVENTIONN/ANAMcGill University Health CentrePhuong-Nam Nathalie Nguyen
Ovarian CancerBTDOCID-1483282069-8590Creation of a virtual human twin as a tool for cancer detection assistance,Création d'un jumeau humain virtuel comme outil d'aide à la détection du cancerNAANY_STAGEN/ANABioTwin
Ovarian CancerC042800
NCT01862081
A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung CancerPHASE1ADVANCED, METASTATICHER2-, HR+, TRIPLE NEGATIVENACIUSSS du Centre-Ouest-de-l’Île-de-MontréalAlessandra Vasconcelos
Cervix CancerCA052-002
NCT04895709
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab in Participants With Advanced Solid Tumors,Étude visant à évaluer le BMS-986340 administré en monothérapie et en association avec le nivolumab chez des participants atteints de tumeurs solides de stade avancéPHASE1, PHASE2ADVANCEDN/AGREATER_THAN_FIRST_LINECentre hospitalier de l'Université de MontréalAdeline Hamon
Endometrial cancerCO2re IntimaNAANY_STAGEN/ANACHU de Québec - Université LavalJosée Allard
Endometrial cancerCO44195
NCT05634499
A Study of Giredestrant in Participants With Grade 1 Endometrial CancerPHASE2NAN/A1re ligneMcGill University Health Centre
Endometrial cancerCO44195
NCT05634499
A Study of Giredestrant in Participants With Grade 1 Endometrial CancerPHASE2NAN/A1re ligneCIUSSS du Centre-Ouest-de-l’Île-de-MontréalAlessandra Vasconcelos
Cervix CancerCONTESSA/NeoConF
NCT04016389
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing SurgeryNAEARLYN/AADJUVANTCHU de Québec - Université LavalMaryse Gingras
Cervix CancerCONTESSA/NeoConF
NCT04016389
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing SurgeryNAEARLYN/AADJUVANTCentre hospitalier de l'Université de Montréal06CHUMDREC Recherche Clinique Gynécologie-oncologie
Ovarian CancerD9720C00001 - PETRA
NCT04644068
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid MalignanciesPHASE1, PHASE2ADVANCED, METASTATICBRCA1/2, PALB2/HDR, RAD51C, RAD51DGREATER_THAN_SECOND_LINE, SECOND_LINECentre hospitalier de l'Université de MontréalAdeline Hamon
Ovarian CancerD9720C00001 - PETRA
NCT04644068
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid MalignanciesPHASE1, PHASE2ADVANCED, METASTATICN/AGREATER_THAN_SECOND_LINE, SECOND_LINECIUSSS du Centre-Ouest-de-l’Île-de-MontréalAlessandra Vasconcelos, Annabelle Dormevil
Ovarian CancerExactis-03
NCT05358639
Combination of Olaparib and Navitoclax in Women With HGSC and TNBCPHASE1RECURRENT, ADVANCED, METASTATICBRCA1/2, PALB2GREATER_THAN_FIRST_LINECentre hospitalier de l'Université de MontréalLynda Abdelguerfi
Ovarian CancerGARNET
NCT02715284
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid TumorsPHASE1ADVANCEDPD-1, PD-L1GREATER_THAN_FIRST_LINEMcGill University Health CentrePhuong-Nam Nathalie Nguyen
Ovarian CancerGARNET
NCT02715284
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid TumorsPHASE1ADVANCEDN/AGREATER_THAN_FIRST_LINECentre hospitalier de l'Université de Montréal06CHUMDREC Recherche Clinique Gynécologie-oncologie
Cervix CancerGO43860
NCT05581004
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid TumorsPHASE1ADVANCED, METASTATIC, RECURRENTN/ASECOND_LINECIUSSS du Centre-Ouest-de-l’Île-de-MontréalDing Yuan Guo
Cervix CancerGOG-3043
NCT04831580
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix CancerNAEARLYN/A1re ligneMcGill University Health CentrePhuong-Nam Nathalie Nguyen
Cervix CancerGOG-3043
NCT04831580
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix CancerNAEARLYN/A1re ligneCentre hospitalier de l'Université de Montréal06CHUMDREC Recherche Clinique Gynécologie-oncologie
Ovarian Cancer, Peritoneal CancerIMGN853-0421
NCT05445778
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA),Mirvetuximab Soravtansine avec Bevacizumab versus Bevacizumab comme entretien dans le cancer de l'ovaire, des trompes de Fallope ou du péritonéal sensible au platine (GLORIOSA)PHASE3RECURRENT, ADVANCEDFRA+, BRCA1/2GREATER_THAN_SECOND_LINECIUSSS de l'Est-de-l'Île-de-MontréalSamara Bloom
Ovarian Cancer, Peritoneal CancerIMGN853-0421
NCT05445778
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA),Mirvetuximab Soravtansine avec Bevacizumab versus Bevacizumab comme entretien dans le cancer de l'ovaire, des trompes de Fallope ou du péritonéal sensible au platine (GLORIOSA)PHASE3RECURRENT, ADVANCEDFRA+, BRCA1/2GREATER_THAN_SECOND_LINECentre hospitalier de l'Université de Montréal06CHUMDREC Recherche Clinique Gynécologie-oncologie
Ovarian Cancer, Peritoneal CancerIMGN853-0421
NCT05445778
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA),Mirvetuximab Soravtansine avec Bevacizumab versus Bevacizumab comme entretien dans le cancer de l'ovaire, des trompes de Fallope ou du péritonéal sensible au platine (GLORIOSA)PHASE3RECURRENT, ADVANCEDFRA+, BRCA1/2GREATER_THAN_SECOND_LINECIUSSS de l'Estrie-CHUSAnnie Bourbonnais
Ovarian Cancer, Peritoneal CancerIMGN853-0421
NCT05445778
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA),Mirvetuximab Soravtansine avec Bevacizumab versus Bevacizumab comme entretien dans le cancer de l'ovaire, des trompes de Fallope ou du péritonéal sensible au platine (GLORIOSA)PHASE3RECURRENT, ADVANCEDFRA+, BRCA1/2GREATER_THAN_SECOND_LINEMcGill University Health CentrePhuong-Nam Nathalie Nguyen
Cervix Cancer, Endometrial cancerKL264-01
NCT04152499
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard TherapiesPHASE1, PHASE2METASTATIC, REFRACTORYHR+, HER2+, TRIPLE NEGATIVEGREATER_THAN_FIRST_LINEMcGill University Health CentrePhuong-Nam Nathalie Nguyen
Endometrial cancerKRT-232-118
NCT05797831
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial CancerPHASE2, PHASE3ADVANCED, RECURRENTP53SECOND_LINECHU de Québec - Université LavalMaryse Gingras
Endometrial cancerKRT-232-118
NCT05797831
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial CancerPHASE2, PHASE3ADVANCED, RECURRENTP53SECOND_LINECentre hospitalier de l'Université de Montréal
Cervix Cancer, Endometrial cancer, Vulvar CancerMK-3475-158
NCT02628067
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)PHASE2ADVANCEDPD-1, PD-L1GREATER_THAN_FIRST_LINECIUSSS du Centre-Ouest-de-l’Île-de-MontréalIvgenya Kosenko
Endometrial cancerMK-4280A-010
NCT06036836
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)PHASE2ADVANCED, METASTATIC, RECURRENTPD-1, PD-L1, PMMRGREATER_THAN_FIRST_LINEMcGill University Health CentrePhuong-Nam Nathalie Nguyen
Endometrial cancerMK-4280A-010
NCT06036836
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)PHASE2ADVANCED, METASTATIC, RECURRENTPD-1, PD-L1, PMMRGREATER_THAN_FIRST_LINECentre hospitalier de l'Université de Montréal06CHUMDREC Recherche Clinique Gynécologie-oncologie
Endometrial cancerMK-4280A-010
NCT06036836
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)PHASE2ADVANCED, METASTATIC, RECURRENTPD-1, PD-L1, PMMRGREATER_THAN_FIRST_LINECHU de Québec - Université LavalMaryse Gingras
Ovarian Cancer, Peritoneal CancerNRG-GY019
NCT04095364
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerPHASE3ADVANCEDP53, TP53GREATER_THAN_FIRST_LINECentre hospitalier de l'Université de Montréal06CHUMDREC Recherche Clinique Gynécologie-oncologie
Cervix Cancer, Ovarian CancerOCEL-01
NCT04260802
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers,Étude visant à évaluer l’innocuité et la pharmacocinétique de l’OC-001 chez les patients atteints de cancers localement avancés ou métastatiquesPHASE1, PHASE2ADVANCED, METASTATICN/AGREATER_THAN_FIRST_LINECentre hospitalier de l'Université de MontréalChantal Légaré, Marie-Ève Rego
Cervix Cancer, Ovarian CancerOCEL-01
NCT04260802
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers,Étude visant à évaluer l’innocuité et la pharmacocinétique de l’OC-001 chez les patients atteints de cancers localement avancés ou métastatiquesPHASE1, PHASE2ADVANCED, METASTATICTRIPLE NEGATIVEGREATER_THAN_FIRST_LINECIUSSS du Centre-Ouest-de-l’Île-de-MontréalIvgenya Kosenko
Endometrial cancerPROMISENAANY_STAGEN/ANACentre hospitalier de l'Université de MontréalFrance Gauthier
Cervix CancerRTOG 0724
NCT00980954
Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical HysterectomyPHASE3EARLYN/AADJUVANTMcGill University Health CentreGinette Ricard
Cervix CancerSENTICOL III - CX6
NCT03386734
International Validation Study of Sentinel Node Biopsy in Early Cervical CancerNAEARLYN/A1re ligneCIUSSS de l'Est-de-l'Île-de-MontréalAudrey Lamoureux, Samara Bloom
Cervix CancerSENTICOL III - CX6
NCT03386734
International Validation Study of Sentinel Node Biopsy in Early Cervical CancerNAEARLYN/A1re ligneCHU de Québec - Université LavalMaryse Gingras
Endometrial cancer, Ovarian CancerSGNDV-005NCT06003231A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2PHASE2ADVANCED, RECURRENTHER2+GREATER_THAN_SECOND_LINEMcGill University Health CentrePhuong-Nam Nathalie Nguyen
Endometrial cancer, Ovarian CancerSGNDV-005NCT06003231A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2PHASE2ADVANCED, RECURRENTHER2+GREATER_THAN_SECOND_LINECHU de Québec - Université LavalMaryse Gingras
Endometrial cancer, Ovarian CancerTH1902-CTR-0001
NCT04706962
TH1902 in Patients With Advanced Solid TumorsPHASE1ADVANCED, METASTATIC, REFRACTORYTRIPLE NEGATIVE, HR+GREATER_THAN_FIRST_LINECentre hospitalier de l'Université de MontréalAdeline Hamon
Endometrial cancer, Ovarian CancerTROPION-PanTumor03 - Gastric
NCT05489211
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)PHASE2ADVANCED, METASTATICN/A1re ligneMcGill University Health CentreRyan Liu
Endometrial cancer, Ovarian CancerTROPION-PanTumor03 - Gastric
NCT05489211
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)PHASE2ADVANCED, METASTATICN/A1re ligneCHU de Québec - Université LavalPhilippe Nadeau
Endometrial cancer, Ovarian CancerTROPION-PanTumor03 - Prostate CancerStudy of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03),PHASE2ADVANCED, METASTATICN/A1re ligneMcGill University Health CentreRodrigo Skowronski
Endometrial cancerXPORT-EC-042NCT05611931Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial CarcinomaPHASE3RELAPSED, ADVANCEDP53GREATER_THAN_FIRST_LINEMcGill University Health CentrePhuong-Nam Nathalie Nguyen
Endometrial cancerXPORT-EC-042NCT05611931Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial CarcinomaPHASE3RELAPSED, ADVANCEDP53GREATER_THAN_FIRST_LINECentre hospitalier de l'Université de MontréalJosée Tremblay